Product Description
A tissue factor-directed antibody-drug conjugate. Tisotumab vedotin showed clinically meaningful and durable antitumour activity with a manageable and tolerable safety profile in women with previously treated recurrent or metastatic cervical cancer. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33845034/)
Mechanisms of Action: TFP Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: Accelerated Approval - Cervical CancerPriority Review - Cervical Cancer *
Approval Status: Approved
Approved Countries: Greece | United States
Approved Indications: None
Known Adverse Events: None
Company: SeaGen
Company Location:
Company CEO:
Additonal Commercial Interests: Zai Lab
Clinical Description
Countries in Clinic: Argentina, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Japan, Korea, Mexico, Netherlands, Norway, Peru, Poland, Puerto Rico, Singapore, South Korea, Spain, Sweden, Taiwan, Turkey, United Kingdom, United States
Active Clinical Trial Count: 14
Highest Development Phases
Phase 3: Cervical Cancer|Uterine Cancer
Phase 2: Colorectal Cancer|Fallopian Tube Cancer|Head and Neck Cancer|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Ovarian Cancer|Pancreatic Cancer|Peritoneal Cancer|Squamous Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SGNTV-003, TV-301 | P3 |
Unknown Status |
Cervical Cancer |
2028-02-28 |
|
| 2017-005076-26 | P2 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2027-11-16 |
|
| SGNTV-001 | P2 |
Unknown Status |
Oncology Solid Tumor Unspecified |
2026-12-31 |
|
| innovaTV 301 | P3 |
Active, not recruiting |
Cervical Cancer |
2026-04-11 |